Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals or view top-rated stocks.

6 Wall Street analysts have issued twelve-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL stock forecasts range from $75.00 to $220.00. On average, they expect Madrigal Pharmaceuticals' stock price to reach $162.29 in the next year. This suggests a possible upside of 104.1% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Madrigal Pharmaceuticals' stock was trading at $84.74 at the beginning of 2022. Since then, MDGL stock has decreased by 6.2% and is now trading at $79.51.
View the best growth stocks for 2022 here.

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our earnings forecast for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.87) by $0.08.

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Madrigal Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (1.07%), Hennion & Walsh Asset Management Inc. (0.35%), SG Americas Securities LLC (0.11%), Assenagon Asset Management S.A. (0.05%), Cambridge Investment Research Advisors Inc. (0.05%) and State Board of Administration of Florida Retirement System (0.04%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals.

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDGL stock can currently be purchased for approximately $79.51.

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $1.36 billion. The biopharmaceutical company earns $-241,850,000.00 in net income (profit) each year or ($15.07) on an earnings per share basis.

Madrigal Pharmaceuticals employs 71 workers across the globe.

Madrigal Pharmaceuticals was founded in 2011.

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.